Tidilan

Quick links to important sections

Tidilan

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tidilan

Property Description
Active ingredient Isoxsuprine (Isoxsuprine Hydrochloride)
Form Oral Tablet (also available as injection)
Pharmacological class Peripheral Vasodilator / Uterine Relaxant (Tocolytic)
Common Patient Group Patients with peripheral vascular conditions and expectant mothers
Origin Synthetic Small Molecule

What Type of Medicine is Tidilan (Isoxsuprine)?

Tidilan is a prescription drug brand primarily containing the active ingredient Isoxsuprine (INN). It is chemically categorized as a Peripheral Vasodilator and a Uterine Relaxant (Tocolytic). This dual functionality allows it to affect smooth muscle tissue in both the circulatory system and the reproductive system.

The use of Isoxsuprine as a tocolytic agent is well-established, distinguishing it from general medications that focus only on blood pressure. It causes direct relaxation of vascular and uterine smooth muscle. This therapeutic focus means the medicine is uniquely relevant in improving circulation and managing premature uterine activity.


What is Tidilan Made Of and How is it Taken?

Isoxsuprine is a synthetic small molecule, classifying it as a non-naturally derived compound. Tidilan is most commonly supplied as an oral tablet taken by mouth, though injectable forms are also available for acute situations.

As a single-ingredient drug, it contains only Isoxsuprine Hydrochloride along with non-active excipients necessary for the tablet form. This stable, manufactured composition ensures patients receive a reliable, consistent dose of the active substance.


What is the General Purpose of Tidilan?

The general purpose of taking Tidilan is to utilize its smooth muscle-relaxing effects to improve blood flow to affected tissues and to reduce the contraction activity of the uterus.

By causing vasodilation (the widening of blood vessels), the drug helps enhance the delivery of oxygen and nutrients to tissues where circulation is restricted. Its uterine relaxing effect helps maintain stability for an expectant mother by delaying the onset of premature contractions.

What side effects are possible with Tidilan?

Possible Side Effects and Safety Information

The official regulatory safety profile for isoxsuprine (Tidilan) defines potential adverse reactions primarily across the cardiovascular and gastrointestinal systems, based on its classification as a peripheral vasodilator and beta-stimulant.


Adverse Reaction Scope

The primary frequency classification for the oral tablet formulation notes that several documented side effects, including Hypotension (low blood pressure), Tachycardia (rapid heartbeat), Chest pain, Nausea, Vomiting, Dizziness, and Severe rash, have been reported "on rare occasion" in official regulatory labeling.

System-organ classes involved in documented adverse reactions include the Vascular/Cardiovascular system, the Gastrointestinal system, the Nervous system, and the Skin and Subcutaneous Tissue.


Serious Safety Considerations

The label documents specific, serious adverse reactions. In the context of use as a tocolytic (uterine relaxant), Pulmonary edema has been reported in mothers treated with medications of this pharmacological class. The occurrence of a Severe rash is explicitly noted as a reaction that requires drug discontinuation.

Population-Specific Safety: Use is contraindicated in the presence of arterial bleeding and immediately postpartum. Furthermore, the safety and effectiveness of isoxsuprine have not been established in pediatric patients. When used in expectant mothers, specific adverse effects such as Hypocalcemia, Hypoglycemia, and Hypotension have been documented in newborns.

Overdose and Emergency Response

️ Tidilan Overdose and When to Seek Help

Tidilan (isoxsuprine) is a vasodilator, and an overdose is typically associated with pronounced cardiovascular effects due to its mechanism of action. While specific fatal toxic doses are not clearly defined, taking a dose significantly higher than prescribed can lead to severe symptoms. The maximum daily dose for isoxsuprine is generally between 80 to 120 mg, and exceeding this, especially all at once, increases the risk of overdose.

Symptoms of Overdose

Symptoms of a Tidilan overdose are primarily linked to excessive vasodilation and cardiac stimulation. They may include:

  • Severe Hypotension: Extreme drop in blood pressure, leading to lightheadedness or fainting.
  • Tachycardia: A significantly fast or irregular heartbeat/palpitations.
  • Central Nervous System Effects: Severe dizziness, confusion, or weakness.
  • Gastrointestinal Distress: Nausea and vomiting.

When to Seek Emergency Help

Immediate medical attention is required if you or someone else has taken more than the prescribed dose of Tidilan or if any of the following severe symptoms occur:

  • Loss of consciousness or fainting.
  • Trouble breathing or chest pain.
  • Seizures or collapse.
  • Persistent or severe weakness and confusion.

Overdose management often involves supportive care for the cardiovascular system and may include interventions like gastric lavage, depending on the amount and time since ingestion. Always contact emergency services or a poison control center immediately if an overdose is suspected.

Therapeutic Uses of Tidilan

Tidilan is a prescription medication used to manage two distinct categories of conditions. Its primary uses are centered on therapeutic support for issues related to blood circulation and the management of certain high-risk pregnancies. In circulatory disorders, such as Peripheral Vascular Disease and conditions like Raynaud's phenomenon, this medicine is used to help alleviate associated symptoms like cramping, pain, and coldness in the limbs.

The medication is also utilized as part of a regimen in obstetrics to manage uterine contractions. This approach is intended to help delay or prevent premature labor in appropriate clinical scenarios, supporting the maintenance of a healthy pregnancy duration.


Quick Facts

  • Therapeutic Support for Poor Peripheral Circulation
  • Regimen for Managing Uterine Contractions
  • Used to Help Relieve Limb Pain and Coldness

Regulatory References

  1. [Review Isoxsuprine Drug Safety and Efficacy Guidance: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=Isoxsuprine

Eligibility and Restrictions for Use

The eligibility profile for Tidilan (Isoxsuprine) is strictly defined by regulatory documents, outlining which populations are approved for use, restricted, or absolutely prohibited.

Eligibility Scope

Category Official Regulatory Statements
Populations for whom use is allowed: Primarily adult patients for approved indications, provided documented contraindications are absent.
Populations for whom use is contraindicated: Patients with arterial bleeding or recent arterial hemorrhage. Patients who are immediately postpartum (after childbirth). Patients with known heart disease or severe anemia.
Age-related eligibility rules: Safety and effectiveness in pediatric patients (children) have not been established. Older adults may require special caution due to potential tolerance issues.
Pregnancy and lactation eligibility status: Pregnancy use is restricted, permitted only when the potential benefit outweighs the potential risk. Lactation use is also restricted, requiring careful assessment of the risk to the infant.

Resulting Eligibility Structure

The official eligibility structure is based on a Contraindicated classification for conditions that pose a severe risk, such as hemorrhage and cardiac compromise. Eligibility is further defined by a Not Established status for pediatric use and a Conditional status for use during pregnancy and lactation. These regulatory classifications directly dictate who can or cannot receive the medicine according to authority documentation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Tidilan (Isoxsuprine) as reported in government regulatory documents.

Official Interaction Profile

The regulatory information for oral Isoxsuprine is primarily structured around pharmacodynamic effects related to its core function as a peripheral vasodilator and a beta-adrenergic stimulant. The official prescribing information does not list any mandatory contraindicated drug combinations for use at recommended doses.

Interaction Type Interacting Substances/Class Official Regulatory Statement
Pharmacodynamic Additive Other Vasodilators or Anti-hypertensive Drugs Co-administration may cause severe hypotension due to additive blood pressure-lowering effects.
Pharmacodynamic Antagonism Non-selective beta-Adrenergic Blockers Use may antagonize or abolish the therapeutic effects of Isoxsuprine.
Additive beta-Stimulation Other beta-Adrenergic Stimulants Combination may increase the risk of associated effects, including maternal and fetal tachycardia.

No explicit warnings regarding metabolic interactions (e.g., CYP enzymes) or specific transporter-mediated interactions are documented in the official regulatory prescribing information. Similarly, there are no documented mandatory timing separation rules requiring that the drug be administered a specific number of hours apart from other medications. Government-aligned health resources advise caution regarding Alcohol (Ethanol) due to the potential for it to increase known central and peripheral effects, such as dizziness.

Mechanism of Action

Tidilan, which contains the active substance Isoxsuprine, functions as a beta-adrenergic receptor agonist. Its primary mechanism involves binding to and activating beta2-adrenergic receptors, which are highly expressed in vascular smooth muscle and uterine smooth muscle tissue.

Upon agonist binding, the G-protein coupled receptor initiates an intracellular cascade. This involves the activation of the stimulatory G protein (Gs), which subsequently stimulates adenylate cyclase.

Activation of adenylate cyclase leads to an increased synthesis of the second messenger cyclic adenosine monophosphate (cAMP) within the cell. The elevated cAMP levels activate protein kinase A (PKA). PKA mediates the phosphorylation of various downstream target proteins, resulting in a net decrease in intracellular calcium ion (Ca^2+) concentration. The reduction in cytoplasmic Ca^2+ concentration inhibits the interaction between actin and myosin, leading to the direct relaxation of smooth muscle cells. System-level physiological consequences include peripheral vasodilation and a resultant decrease in vascular resistance.

Dosage and Administration Information

How Tidilan is Used: General Administration Guidelines

Tidilan, which contains the active ingredient Isoxsuprine, is primarily utilized via the oral route for long-term use, though injectable forms are available for acute, restricted contexts. The medicine is supplied as oral tablets, typically in 10 mg and 20 mg strengths, which defines the standard dosing range for adults.


Standard Dosage and Frequency

The standard oral dose for adults is 10 mg to 20 mg per administration, and it is usually taken on a divided daily schedule, specifically three or four times daily. This regimen is designed to maintain consistent levels of the compound throughout the day. It is essential to follow the prescribed frequency; if a dose is missed and it is nearly time for the next scheduled dose, the standard protocol is to skip the missed dose and not take a double amount.


Administration Conditions and Restrictions

Timing and Intake: The tablets should be taken with water. If the oral dose causes stomach discomfort, it may be taken with meals, milk, or an antacid.

Acute Use Constraint: The parenteral (IV/IM) form of Isoxsuprine, which may be used in certain acute obstetrical scenarios, is subject to strict clinical constraints, including a maximum duration of 48 hours and the requirement for continuous specialist and hospital supervision. The safety and effectiveness of the drug have not been established in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tidilan (Isoxsuprine)

Evidence for Use in Managing Preterm Uterine Activity

Research has primarily focused on evaluating Isoxsuprine as a tocolytic agent, a type of medicine that has been studied as a tocolytic agent. The existing evidence base consists mainly of older, smaller randomized controlled trials (RCTs) and subsequent systematic reviews synthesizing these findings, alongside more recent prospective observational studies that track outcomes in contemporary clinical practice. These studies focused on pregnant women experiencing symptoms related to preterm labor, often comparing the drug to a placebo or, in some cases, to other uterine relaxant medications.

Key measures evaluated were the discontinuation of uterine contractions, the time elapsed before delivery (pregnancy prolongation, often tracked over 24 to 48 hours or longer), and various neonatal health markers. Some trials described patterns of short-term prolongation of pregnancy compared to control groups. However, for long-term effectiveness of the oral tablet form for maintenance therapy and observed outcomes related to neonatal health, findings were mixed or limited across the research landscape.

Evidence for Use in Peripheral Circulatory Conditions

Research exploring the use of Isoxsuprine as a peripheral vasodilator—a medication that was studied for its potential association with changes in blood flow in the limbs—is largely based on older, small-scale randomized crossover studies and comparative trials. These studies included adult subjects with conditions such as Peripheral Vascular Disease (PVD).

In these trials, researchers examined both objective physiological markers and patient-reported outcomes describing perceived discomfort. Objective outcomes included measured changes in blood flow and functional capacity, such as walking distance. The evidence for this indication is often characterized as low-level. Some controlled studies noted that objective measurements did not show substantial patterns of change, while subjective symptom reports varied in the observed populations.

What the Research Landscape Shows About Consistency and Gaps

The overall evidence quality varies across studies. For the tocolysis indication, a key research limitation is the reliance on older, smaller trials and the lack of contemporary comparative evidence against newer, established therapies. These gaps mean that while findings describe group patterns observed in the studies, the research does not determine whether an individual will respond similarly, and evidence consistency remains low. Long-term effects are not fully established, and more research is ongoing to better characterize the full spectrum of outcomes.

Key Studies & References

  1. Label: ISOXSUPRINE HYDROCHLORIDE tablet - DailyMed (FDA-associated label information classified as Possibly Effective)

Frequently Asked Questions (FAQ)

Common questions about Tidilan (FAQ)


Q: Is Tidilan approved by the FDA?

A: No. The Food and Drug Administration (FDA) officially withdrew its approval for drug products containing Isoxsuprine from the U.S. market in 2022.


Q: Is Tidilan a blood thinner?

A: No, Tidilan is classified as a Peripheral Vasodilator. It works by relaxing blood vessels to improve blood flow, but its function is not to prevent blood from clotting like a blood thinner (anticoagulant).


Q: Is Tidilan available over the counter in any country?

A: In major regulatory systems like the U.S., Tidilan (Isoxsuprine) is classified as a Human Prescription Drug. This means it requires a valid prescription from a licensed healthcare provider and is not available over the counter.


Q: What is the difference between the brand name and the generic version of Tidilan?

A: Tidilan is the brand name for the active ingredient, which is called Isoxsuprine Hydrochloride. In regulatory terms, both brand and generic versions contain the same active chemical substance.


Q: Is Tidilan known by any other names internationally?

A: Yes, the active ingredient is known generically as Isoxsuprine Hydrochloride. In different countries or at different times, it has been sold under various brand or proprietary names, such as Vasodilan.


Q: Is Tidilan a new or well-established medication?

A: Isoxsuprine has been on the market for an extended period, suggesting it is well-established rather than new. However, regulatory documents indicate that the FDA officially withdrew approval for products containing Isoxsuprine from the U.S. market in 2022.


Q: How quickly does Tidilan usually start to work?

A: Official pharmacokinetic data describes how quickly the medicine enters the body. The highest concentration of the drug in the bloodstream (known as peak plasma concentration) typically occurs about one hour after an oral dose is taken.


Q: How long does the effect of a single dose of Tidilan typically last?

A: The body processes the drug relatively quickly. The plasma half-life of the active ingredient, Isoxsuprine, is reported in regulatory documents to be about 1.5 hours. The half-life describes the time it takes for the amount of drug in the body to be reduced by half.


Q: How long after stopping Tidilan will it be completely out of my system?

A: Based on the drug’s reported half-life of 1.5 hours, the active ingredient is generally considered to be almost completely cleared from the system after approximately five half-lives. This process would take about 7.5 hours.


Q: What are the most commonly reported mild side effects of Tidilan?

A: Based on regulatory patient information, commonly reported mild side effects can include dizziness, a feeling of warmth (flushing), weakness, and issues in the stomach or gut, such as nausea or stomach pain. Any experienced effects should be discussed with a healthcare provider.


Q: Is it common to feel tired after taking Tidilan?

A: Official product information states that Tidilan may cause drowsiness or dizziness. This is a recognized effect on the central nervous system. Patients may notice this when first starting the medication.


Q: Can taking Tidilan cause changes to sleep patterns?

A: The medication may cause drowsiness, which is an effect on the central nervous system. This effect, which may include the feeling of being tired, could potentially lead to alterations in a person's typical sleep pattern.


Q: Is it possible to be allergic to Tidilan?

A: Yes, an allergic reaction to Tidilan is possible. An allergic reaction is explicitly noted in patient information as a condition where the medicine should not be used (a contraindication).


Q: What should I do if a side effect seems concerning?

A: If a serious or concerning side effect, such as a severe rash, chest pain, or a rapid heartbeat, is experienced, official guidance stresses the importance of contacting a healthcare professional immediately. This information is intended to help patients recognize symptoms that require prompt medical attention.


Q: Can Tidilan affect my ability to drive or operate machinery?

A: Yes, official patient guidance advises caution. Because the medication may cause dizziness or drowsiness, activities requiring full alertness should be avoided until an individual knows how they respond to the medicine.


Q: What does 'contraindicated' mean in relation to Tidilan?

A: The term 'contraindicated' is used in official documentation to mean that the medicine should not be used because the potential risks are considered too great. For Tidilan, contraindications include conditions like arterial bleeding or use immediately following childbirth.


Q: Is there a link between Tidilan and long-term heart health?

A: Official documents note that the drug should not be used in individuals with pre-existing heart conditions. The drug is contraindicated in patients who have known heart disease, angina, or have recently had a heart attack.


Q: Why are people with kidney problems sometimes advised against using Tidilan?

A: Clinical studies, particularly those related to the drug’s use as a uterine relaxant, have sometimes included renal disease (kidney problems) as an exclusion criterion for patient participation. The inclusion of renal disease as an exclusion criterion indicates a need for careful consideration when the medicine is prescribed to individuals with pre-existing kidney conditions.


Q: Is there a risk of becoming dependent on Tidilan?

A: Regulatory documents confirm that Tidilan (Isoxsuprine) is not classified as a controlled substance. It is not listed in the DEA schedules for drugs with potential for abuse or dependency.


Q: Why is the dosage different for different people?

A: The dose and frequency of taking the medication are determined by a healthcare provider based on individual patient needs. The amount of medicine used depends on the specific medical problem for which the medicine is being prescribed.


Q: What is the maximum period of time Tidilan is typically used for?

A: The length of time a person takes the oral medication depends entirely on the specific medical problem being treated and a doctor’s assessment. The official 48-hour maximum duration only applies to the injectable form when used in specific, acute hospital settings.


Q: What does the research say about stopping Tidilan abruptly?

A: Patient guidance advises against stopping the medication on your own, even if it is felt that the medicine is not working. Changes in the use of this medicine, including stopping or altering the dose, are typically advised to be reviewed with a healthcare professional.


Q: Can Tidilan be crushed, split, or chewed?

A: Some strengths of the oral tablet are described as being 'scored,' which typically indicates the tablet may be split. However, specific regulatory instructions regarding whether the tablet can be crushed or chewed before swallowing are not explicitly provided in patient documentation.


Q: Why is my doctor asking me about other drugs I use before prescribing Tidilan?

A: A healthcare provider asks about other medications because Tidilan can have additive effects with certain heart or blood pressure drugs, such as anti-hypertensives. Knowing the complete drug profile helps professionals monitor and manage potential side effects, like severe drops in blood pressure (hypotension).


Q: Can Tidilan interact with common supplements like multivitamins?

A: General patient guidance emphasizes the need to check with a healthcare professional before using any other medicines, including over-the-counter products, vitamins, and supplements. This is to ensure no unknown interactions occur.


Q: Does Tidilan interact with herbal remedies like St. John's Wort?

A: Patient guidance stresses the importance of consulting a healthcare professional before using any herbal products. This precautionary step is necessary because the potential for interactions with herbal remedies is not always fully documented.


Q: What are the known interactions between Tidilan and common pain relievers?

A: The official interaction profile indicates that when Tidilan is combined with certain types of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are common pain relievers, there may be an increased risk of elevated blood pressure (hypertension).


Q: Are there any specific foods I should avoid while using Tidilan?

A: According to official patient information, there are no specific foods or mandatory dietary restrictions that must be followed while taking this medication. If stomach upset is experienced, guidance indicates the tablets may be taken with food, milk, or an antacid.


How should Tidilan be stored and disposed of?

Official Storage and Disposal Requirements

Tidilan (isoxsuprine) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with permitted excursions to 15 C to 30 C. The product must be kept from freezing, stored away from excess heat, and protected from light and moisture.

Storage Constraint Requirement
Container Must be kept tightly closed and stored in the original container.
Child Safety Must be kept out of the reach of children and pets.
Shelf-Life Do not use after the expiration date has passed.

Unused or expired medication should be disposed of through a drug take-back program. If one is unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash. The tablets should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tidilan found in:

A-Z Index: